Partial
Needs Revision
Patient Risk:
Moderate
Summary
Some claims align with the label’s antiplatelet/stroke-risk reduction and bleeding risk, but multiple claims are unsupported or not consistent with the specific FDA-labeled product (Aspirin and extended-release dipyridamole capsules) and omit key prescribing specifics (e.g., exact indication population and dosing instructions). Several statements about dosing (81–100 mg), pregnancy/breastfeeding, and broad preventive use for general high-risk groups are not supported by the supplied label excerpts.
Category Scores
Accurate Statements
Aspirin inhibits platelet aggregation.
Supported by clinical pharmacology: “additive antiplatelet effects of dipyridamole and aspirin.” (12 CLINICAL PHARMACOLOGY)
Aspirin's antiplatelet properties reduce the risk of blood clots and subsequent strokes.
Supported in concept by labeled antithrombotic/antiplatelet action and labeled indication to reduce stroke risk. (12 CLINICAL PHARMACOLOGY; 1 INDICATIONS AND USAGE)
Aspirin can cause gastrointestinal bleeding.
Supported by warnings with ESPS2: “annualized event rate for gastrointestinal bleeding was 2.97%/year…” (5 WARNINGS AND PRECAUTIONS)
Aspirin can interact with warfarin and increase the risk of bleeding.
Supported: “Aspirin can displace warfarin… leading to prolongation… and the bleeding time… increasing bleeding risk.” (7 DRUG INTERACTIONS)
Aspirin therapy is described as cost-effective for stroke prevention compared to more expensive medications.
Unsupported by provided label excerpts (not present in supplied sections).
Aspirin inhibits platelet aggregation.
Supported by “additive antiplatelet effects of dipyridamole and aspirin.” (12 CLINICAL PHARMACOLOGY)
Unsupported Statements
When platelets aggregate, they form blood clots that can block blood flow to the brain, leading to a stroke.
The provided label excerpts support antiplatelet action and stroke-risk reduction, but do not explicitly state this mechanistic chain as written.
A study in the New England Journal of Medicine found aspirin reduced the risk of stroke by 25% in patients with a history of cardiovascular disease.
No such NEJM study or 25% figure is supported by the supplied label excerpts. Label clinical studies cite ESPS2 (14 CLINICAL STUDIES).
A study in the Journal of the American Medical Association found aspirin was effective in preventing strokes in patients with atrial fibrillation.
No such JAMA study or atrial fibrillation population/stated claim is supported by the supplied label excerpts.
Aspirin is recommended for individuals at high risk of cardiovascular events.
Label indication is specific: patients with transient ischemia of the brain or completed ischemic stroke due to thrombosis. The supplied label does not support broad recommendation for general high-risk cardiovascular populations. (1 INDICATIONS AND USAGE)
Aspirin is recommended for patients with a history of cardiovascular disease (heart attack, stroke, or peripheral artery disease) to prevent future events.
The supplied label indication is specifically for reducing stroke risk in TIA or completed ischemic stroke due to thrombosis, not a generalized history-of-CVD statement. (1 INDICATIONS AND USAGE)
Individuals with uncontrolled high blood pressure are at increased risk of cardiovascular events and should consider taking aspirin.
No such recommendation or BP-based consideration is supported in the provided label excerpts.
People with diabetes are at higher risk of cardiovascular disease and should discuss aspirin therapy with their healthcare provider.
No such diabetes-specific discussion/recommendation is supported by the provided label excerpts.
Individuals with a family history of heart disease or stroke should consider taking aspirin to reduce their risk.
No such family-history-based recommendation is supported by the provided label excerpts.
Aspirin can cause stomach ulcers and bleeding, particularly in individuals with a history of gastrointestinal problems.
The label excerpt supports avoiding aspirin in patients with a history of active peptic ulcer disease, but the specific phrasing about “stomach ulcers” and “particularly” is not directly supported as written. (5 WARNINGS AND PRECAUTIONS)
Some people may have allergic reactions to aspirin, which can cause hives, itching, and difficulty breathing.
The label supports severe urticaria/angioedema/bronchospasm with aspirin-related hypersensitivity, but the specific symptom set (itching, difficulty breathing) is not directly supported as written. (4.2 Allergy)
The average cost of aspirin in the United States is approximately $0.25 per tablet.
No cost information is provided in the supplied label excerpts.
Aspirin therapy is described as cost-effective for stroke prevention compared to more expensive medications.
No cost-effectiveness statements are provided in the supplied label excerpts.
The recommended dosage of aspirin for stroke prevention is typically 81–100 mg per day.
The supplied label provides dosing for Aspirin and Extended-Release Dipyridamole Capsules: “one capsule given orally twice daily” but does not state 81–100 mg/day. Also, this product is a combination (aspirin immediate-release + extended-release dipyridamole). (2 DOSAGE AND ADMINISTRATION)
Individuals with a history of gastrointestinal problems, bleeding disorders, or allergic reactions to aspirin should avoid taking it.
The label excerpt specifically advises avoiding with active peptic ulcer disease and discusses bleeding risk; it does not support this broad set (“bleeding disorders” and “allergic reactions” as phrased) as an explicit contraindication/avoidance statement in the provided excerpts.
Aspirin is not recommended for pregnant or breastfeeding women because it can increase the risk of bleeding and other complications.
No pregnancy or breastfeeding information is included in the supplied label excerpts.
Stopping aspirin abruptly may increase the risk of cardiovascular events.
No statement about abrupt discontinuation increasing risk of cardiovascular events is included in the supplied label excerpts.
Contradictions
Low
AI Statement
The recommended dosage of aspirin for stroke prevention is typically 81–100 mg per day.
Label Reference
Label dosing for Aspirin and Extended-Release Dipyridamole Capsules: “one capsule given orally twice daily…” and product-specific guidance; supplied label does not support 81–100 mg/day. (2 DOSAGE AND ADMINISTRATION)
Important Omissions
Indication specificity: the label indicates use to reduce risk of stroke in patients with transient ischemia of the brain or completed ischemic stroke due to thrombosis (not general high-risk cardiovascular populations).
Importance:
Moderate
Correct administration instructions: capsules are to be swallowed whole without chewing, and not interchangeable with component tablets; dosing is one capsule twice daily (morning/evening).
Importance:
Moderate
Contraindication detail: aspirin contraindicated in NSAID hypersensitivity/aspirin allergy syndromes and in children/teenagers with viral infections (Reye syndrome), which is materially different from the broad 'avoid if allergic' claim.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported/incorrectly specified dosing (81–100 mg/day) and broad preventive-use claims not tied to the labeled TIA/completed ischemic stroke population could lead to inaccuracy in treatment selection or dosing. Pregnancy/breastfeeding and stopping-therapy statements are unsupported by the provided label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
Yes |
| Hallucination Risk |
Moderate |
Recommendation
Needs Revision
Primary Issue
Multiple claims are unsupported by the supplied prescribing information, including broad indications, specific study citations/jurisdictions and effect sizes, pregnancy/breastfeeding guidance, abrupt discontinuation risk, and an incorrect/generalized dose range that does not match the labeled product dosing.
Suggested Improvement
Restrict indication language to the labeled population (TIA or completed ischemic stroke due to thrombosis), replace the generalized 81–100 mg/day claim with the labeled regimen for Aspirin and Extended-Release Dipyridamole Capsules (one capsule orally twice daily; swallow whole; not interchangeable), and limit safety/dosing/eligibility statements to those explicitly present in the supplied label sections (bleeding risk, specific hypersensitivity/contraindication details, and warfarin interaction).